Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., . . . Shen, L. (2021). Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single‐arm phase II study. Wiley.
Cita Chicago Style (17a ed.)Peng, Zhi, et al. Efficacy and Safety of a Novel Anti‐HER2 Therapeutic Antibody RC48 in Patients with HER2‐overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single‐arm Phase II Study. Wiley, 2021.
Cita MLA (8a ed.)Peng, Zhi, et al. Efficacy and Safety of a Novel Anti‐HER2 Therapeutic Antibody RC48 in Patients with HER2‐overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single‐arm Phase II Study. Wiley, 2021.